Metabolomics in Medicine

Metabolomics is the large-scale study of small-molecule metabolites—sugars, lipids, amino acids, and other intermediates—in cells, tissues, or biofluids. Analytical platforms (mass spectrometry, nuclear magnetic resonance) and bioinformatics enable profiling of hundreds or thousands of metabolites in a single sample. In medicine, metabolomic signatures can distinguish disease states, predict progression or response to therapy, and reveal perturbed pathways. Applications are emerging in oncology (e.g. tumour typing, monitoring), neurology (e.g. neurodegenerative and metabolic disorders), cardiometabolic disease, and infectious disease. The metabolome sits downstream of genome and proteome and reflects environment, diet, and physiology, offering a dynamic view of health and disease.

The technology addresses the need for biomarkers that capture functional state and heterogeneity. Metabolic rewiring is a hallmark of many diseases; metabolomics can stratify patients, guide treatment selection, and monitor response. It also supports drug development by characterising mechanism and toxicity. Challenges include standardisation of protocols, reference databases, and interpretation of complex, high-dimensional data. Clinical validation and regulatory acceptance are advancing for specific indications and assays.

As instrumentation becomes more accessible and reference datasets grow, metabolomics is likely to be integrated into routine and precision medicine alongside genomics and other omics. It may contribute to early detection, subtype classification, and therapeutic monitoring in a range of conditions.